Medically reviewed by Gagandeep Brar, MD Key Takeaways A high platelet count can lead to blood clots and bleeding, which can ...

When acute bleeding occurs in patients with ET-associated AvWS, the investigators said treatment should focus on rapid ...

Rami Komrokji, M.D.: Once we establish a diagnosis, our next step is thinking of the risk of a disease, because as you mentioned, those diseases are serious, but the risks vary. Maybe you can tell us ...

71% (12/17) showed a decrease in Total Symptom Score (TSS). 53% (9/17) showed a ≥50% decrease in TSS. Patients with all genotypes identified in the study (CALR, JAK2 V617F, Triple Negative) responded ...

Elevated absolute eosinophil counts and absolute basophil counts (ABC) are associated with reduced overall survival in essential thrombocythemia. In polycythemia vera, higher ABC correlates with ...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...

Dr. Douglas Tremblay of the Ichan School of Medicine explains the necessity of cytoreductive therapy for patients with MPNs such as essential thrombocythemia and polycythemia vera. Cytoreduction is ...

Over the past 35 years, interferons have been explored in various formulations for the management of Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), such as essential ...

An open-label, multicenter, expanded access study assessing the safety and efficacy of oral ruxolitinib administered to patients with primary myelofibrosis (PMF), post-polycythemia myelofibrosis (PPV ...

If you have the JAK2 V617F mutation, are aged 18-74 years old, do not smoke, do not have any known autoimmune disease, and attend medical checks at UAB regularly, you may be eligible for our study!